

SEQIRUS FLU UPDATE #2

Afluria® Quad
Inactivated quadrivalent influenza vaccine

Dear Healthcare Professional,

We are anticipating the release of this season's flu vaccine, Afluria® Quad, on Monday 16th March.

The Afluria® Quad Junior stock will be available from 1st April.

There has been increased interest in flu vaccine this year following the media attention on COVID-19, and Seqirus and HCL are putting in place measures to ensure a smooth delivery of stock at the start of the season.

This year's supply of flu vaccine includes an additional 400,000 doses or 30% more than the supply for last year, so there should be plenty of stock to vaccinate everyone who wants it.

The HCL online ordering system is now open, so place your order now and it will be processed as soon as the flu stock is released. <http://www.hcl.co.nz/>

If you have any queries with ordering please contact HCL directly at HCL Customer Services 0508 425 358 or email: orders@healthcarelogistics.co.nz

Please be aware when ordering **Afluria Quad** that orders are taken in **boxes** (not doses), and there are **10 doses in a box**. So if you order 10 boxes on the HCL online site, you will receive 100 doses.

Afluria Quad Junior are ordered as single doses.

| | Afluria Quad 2020 | Afluria Quad Junior 2020 |
|-------------------|--------------------------------|---------------------------------|
| Pack size | 10 single-dose syringes / pack | 1 single-dose syringe / pack |
| Pharmacode | 2581434 | 2581442 |
| HCL material code | 1153792 | 1153793 |

Thanks to those who responded to our request for email addresses for future communications, we had a great response.

Unfortunately the email address was incorrect, so if you emailed a reply can you please resend your details to: nzadmin@seqirus.com

Or complete and fax this form to Seqirus on 09 377 1518

Yes I would like to receive influenza updates from Seqirus

Name:

Email:

Company:

Barnes Bins delivery details

This season you can return Barnes Bins to ProPharma depots for reuse. This is at your own expense. If dropping them off please phone first. If you are sending by courier, there is no need to phone, but you will need to arrange and pay for your own courier.

ProPharma contact details:

WHANGAREI, 2-6 Maunu Road. Ph: 09 438 9519

HAMILTON, Zone 2 - 51 Gallagher Drive, Melville. Ph: 07 957 8199

PALMERSTON NORTH, 5 David Street. Ph: 06 952 0039

WELLINGTON, 3/8 McCormack Place, Ngauranga.
Ph: 04 576 1830

DUNEDIN, 38 Leith St, Dunedin. Ph: 03 474 9150

Flu stickers, badges and lollipops

If you require patient 'I've been immunised' stickers, lollipops and/or 'Get immunised' staff badges please contact Carol Frisby-Shilton on Carol.Frisby-Shilton@seqirus.com. To respect the environment please retain your badge for future flu seasons, as we will not be producing new badges each year.



If you have any questions, please don't hesitate to contact us.

Kind regards,

Head Office -

Jill Desborough, Marketing Manager Ph: 09 377 1520

Central/North/West Auckland & Northland -

Paul Kelly Ph: 021 383 723

Central/East/South Auckland -

Praveen Nalam Ph: 027 482 1305

Central North Island -

Brian Booth Ph: 027 230 6011

South Island & Wellington -

Simonne Findlater Ph: 027 485 7812

AFLURIA® QUAD and AFLURIA® QUAD JUNIOR are funded prescription medicines – restrictions apply. AFLURIA® QUAD and AFLURIA® QUAD JUNIOR are inactivated split virion quadrivalent influenza vaccines, single dose pre-filled glass syringes containing 0.5 mL or 0.25 mL, respectively, of suspension for injection. Indicated for the prevention of influenza caused by the four A and B virus types contained in the vaccine. Each dose contains 15 µg or 7.5 µg, respectively, of haemagglutinin antigens for each of the following strains: A/Brisbane/02/2018 (H1N1)pdm09-like virus; A/South Australia/34/2019 (H3N2)-like virus; B/Washington/02/2019-like virus; and B/Phuket/3073/2013-like virus.

CONTRAINDICATIONS: Infants younger than 6 months of age. Previous anaphylaxis following a dose of any influenza vaccine or anaphylaxis following exposure to any component of the vaccine, excluding egg protein. Postpone in patients with acute febrile illness. **PRECAUTIONS:** Manage any fever, febrile convulsions, or anaphylactic reactions; consider interactions with other vaccines, medications, or laboratory tests; history of anaphylaxis to egg, history of Guillain-Barré syndrome which has occurred within 6 weeks of previous influenza vaccination. Response may be lower in immunocompromised patients and people aged 65 years or older. **ADVERSE EFFECTS:** Common injection site reactions e.g. pain, swelling, and redness; AFLURIA® QUAD: headache, myalgia, malaise, nausea, chills, vomiting, and fever; AFLURIA® QUAD JUNIOR: irritability, diarrhoea and loss of appetite. **ADMINISTRATION:** Shake before administering via intramuscular or deep subcutaneous injection. **DOSAGE:** AFLURIA® QUAD – A single 0.5 mL dose is required for adults and children from 3 years of age; children 3–8 years not previously vaccinated require two doses given at least four weeks apart. AFLURIA® QUAD JUNIOR – A single 0.25 mL dose is required for infants and children 6–35 months of age; infants and children not previously vaccinated require two doses given at least four weeks apart. Before prescribing, review the AFLURIA® QUAD and AFLURIA® QUAD JUNIOR Data Sheet (November 2019) at www.medsafe.govt.nz, or from Seqirus (NZ) Ltd, Auckland. AFLURIA® QUAD and AFLURIA® QUAD JUNIOR are registered trademarks of Seqirus UK Ltd. NZ/AQIV0320/0050 TAPS DA2042ER. INSIGHT 9965